Inogen (NASDAQ:INGN) vs. Envoy Medical (NASDAQ:COCH) Head-To-Head Contrast

Envoy Medical (NASDAQ:COCH) and Inogen (NASDAQ:INGN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends and earnings.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Envoy Medical and Inogen, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Envoy Medical	0	0	2	0	3.00
Inogen	1	2	1	0	2.00

Envoy Medical presently has a consensus price target of $6.00, indicating a potential upside of 19.05%. Inogen has a consensus price target of $7.50, indicating a potential upside of 11.94%. Given Envoy Medical’s stronger consensus rating and higher possible upside, research analysts clearly believe Envoy Medical is more favorable than Inogen.

Risk & Volatility

Envoy Medical has a beta of 2.68, suggesting that its stock price is 168% more volatile than the S&P 500. Comparatively, Inogen has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500.

Profitability

This table compares Envoy Medical and Inogen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Envoy Medical	N/A	N/A	-100.39%
Inogen	-32.46%	-38.98%	-27.03%

Valuation & Earnings

This table compares Envoy Medical and Inogen’s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Envoy Medical	$320,000.00	308.70	-$29.91 million	N/A	N/A
Inogen	$315.66 million	0.50	-$102.45 million	($4.41)	-1.52

Envoy Medical has higher earnings, but lower revenue than Inogen.

Institutional & Insider Ownership

8.6% of Envoy Medical shares are owned by institutional investors. Comparatively, 89.9% of Inogen shares are owned by institutional investors. 0.7% of Envoy Medical shares are owned by company insiders. Comparatively, 0.6% of Inogen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Envoy Medical beats Inogen on 9 of the 12 factors compared between the two stocks.

About Envoy Medical

Envoy Medical, Inc., a hearing health company, provides medical technologies for the hearing loss spectrum. Its products include personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc. in September 2023. Envoy Medical, Inc. was founded in 1995 and is headquartered in White Bear Lake, Minnesota.

About Inogen

Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Simeox airway clearance; batteries; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.